Do Weight-Loss Drugs Cause Hair Loss? Part 5 – Susceptibility
The latest science behind GLP-1 medications, scalp shedding, possible mechanisms and recovery
Evidence review and consumer guide | Last reviewed: July 2026
Why is the scalp affected more than eyelashes and eyebrows?
Short answer: Scalp hair grows longer and sheds more visibly than eyebrows or eyelashes — so it’s noticed more, not necessarily affected more.
The apparent preservation of eyelashes and eyebrows is intriguing, but it does not rule out telogen effluvium. Scalp, eyebrow and eyelash follicles are not interchangeable.
Scalp anagen lasts for years, allowing hairs to grow long. Eyelash and eyebrow anagen is much shorter, and their cycles, follicular size, local signalling environment and hormonal responsiveness differ. A trigger can therefore produce visible diffuse scalp shedding without causing an equally obvious change in shorter facial hairs.
Scalp shedding is also easier to detect. Long hairs accumulate in brushes, showers and clothing. A comparable proportional change in eyelashes may be much less noticeable unless it is severe. Eyebrow and eyelash involvement can occur in major systemic illness, nutritional deficiency, endocrine disease or alopecia areata, but it is not required for the diagnosis of telogen effluvium.
Nevertheless, the predominantly scalp-based pattern supports further investigation of follicle-specific biology. Differences in androgen sensitivity, Wnt/β-catenin signalling, IGF-1, prostaglandins, local receptor expression and stem-cell activation may eventually help explain why scalp follicles appear more vulnerable.
Who may be more susceptible?
Short answer: Rapid weight loss, low food or protein intake, existing pattern hair loss, and being female are the factors most linked to higher risk.
Rapid or large weight loss
The faster and greater the weight reduction, the larger the metabolic adjustment. Clinical trial and post-marketing observations suggest that hair-loss reports may track with the magnitude of weight loss, although this relationship has not been quantified precisely enough to predict individual risk.
Low food or protein intake
People experiencing strong appetite suppression, persistent nausea or food aversion may struggle to meet nutritional requirements. The risk is likely to be greater when total intake remains very low for months.
Pre-existing androgenetic alopecia
A temporary telogen shed can expose underlying miniaturisation. Someone with previously subtle pattern loss may suddenly see more scalp because the normal background density has fallen. When the telogen effluvium recovers, some density may return, but the underlying pattern loss remains.
Female sex and hormonal transition
Women appear disproportionately represented in reported cases. This may reflect biological susceptibility, iron deficiency, menopause, postpartum history, longer hair making shedding easier to detect, or a greater likelihood of seeking medical advice. Current data cannot separate these factors fully.
Previous telogen effluvium or chronic illness
People whose follicles have recently been disrupted by infection, surgery, autoimmune activity, severe stress or another medication may have less reserve when a second metabolic trigger occurs.
Thyroid or nutritional abnormalities
Iron deficiency, anaemia, thyroid disease, folate or B12 deficiency and severe dietary restriction can each contribute to diffuse hair loss and should not be attributed automatically to the weight-loss medicine.
Could GLP-1 therapy expose existing pattern hair loss?
Short answer: Yes — temporary shedding can reveal thinning that was already there but hidden by higher hair density.
Yes. This may be one of the most clinically important explanations for persistent thinning after an initial shed.
In pure telogen effluvium, the density usually improves after the trigger settles. In androgenetic alopecia, susceptible follicles are progressively miniaturising. When both processes occur together, temporary shedding can reveal a pattern that was previously concealed by higher overall density.
Clues include greater thinning over the crown, parting or frontal scalp; variation in shaft diameter; a family history of pattern loss; and incomplete restoration after the shedding phase has ended. Dermoscopic assessment can help distinguish miniaturisation from uniform telogen shedding.